These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16084667)

  • 1. Differentiation therapy of cancer. Potential advantages over conventional therapeutic approaches targeting death of cancer/tumor cells.
    Cao T; Heng BC
    Med Hypotheses; 2005; 65(6):1202-3. PubMed ID: 16084667
    [No Abstract]   [Full Text] [Related]  

  • 2. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active targeting schemes for nanoparticle systems in cancer therapeutics.
    Byrne JD; Betancourt T; Brannon-Peppas L
    Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor of apoptosis proteins as targets for anticancer therapy.
    Fulda S
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1255-64. PubMed ID: 17892425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-responsive nanoparticles for cancer drug delivery.
    Shen Y; Tang H; Radosz M; Van Kirk E; Murdoch WJ
    Methods Mol Biol; 2008; 437():183-216. PubMed ID: 18369970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles for drug delivery in cancer treatment.
    Haley B; Frenkel E
    Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR guided cancer treatment system for an elevated therapeutic index - a macroscopic approach.
    Myhr G
    Med Hypotheses; 2008; 70(3):665-70. PubMed ID: 17765401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cancer cells with biotin-dendrimer conjugates.
    Yang W; Cheng Y; Xu T; Wang X; Wen LP
    Eur J Med Chem; 2009 Feb; 44(2):862-8. PubMed ID: 18550227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas.
    Klemke CD; Goerdt S; Schrama D; Becker JC
    J Dtsch Dermatol Ges; 2006 May; 4(5):395-406. PubMed ID: 16686607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freezing-assisted intracellular drug delivery to multidrug resistant cancer cells.
    Teo KY; Han B
    J Biomech Eng; 2009 Jul; 131(7):074513. PubMed ID: 19640149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical mechanisms and methods employed in drug delivery to tumors.
    Besić E
    Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
    Schiffelers RM; Storm G
    Int J Pharm; 2008 Dec; 364(2):258-64. PubMed ID: 18773947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cancer stem cell].
    Sakashita H; Ieta K; Haraguchi N; Inoue Y; Yoshizawa Y; Mori M
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1721-9. PubMed ID: 18030004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new probe for targeting drug delivery system.
    Yu Z; Wang B; Sui J; Feng Y; Zheng C
    Med Hypotheses; 2009 Jan; 72(1):43-4. PubMed ID: 18829175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cell targeted agents: therapeutic approaches and consequences.
    Chumsri S; Burger AM
    Curr Opin Mol Ther; 2008 Aug; 10(4):323-33. PubMed ID: 18683096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery.
    Kim YI; Chung JW
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):791-802. PubMed ID: 19090739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery to tumours: recent strategies.
    Reddy LH
    J Pharm Pharmacol; 2005 Oct; 57(10):1231-42. PubMed ID: 16259751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs.
    Lacko AG; Nair M; Prokai L; McConathy WJ
    Expert Opin Drug Deliv; 2007 Nov; 4(6):665-75. PubMed ID: 17970668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.